Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: Myeloproliferative Disorders trials

The registry lists 17 Myeloproliferative Disorders studies with Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as lead sponsor. 0 are open to participants now and 4 have results posted.

Phase 1 10Phase 2 5Phase 3 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft MalignanciesCompletedNCT02556931Phase 2Results posted
• Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT00425477Phase 2Results posted
• Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic CancerCompletedNCT00134017Phase 2Results posted
• Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic CancerCompletedNCT00134004Phase 2Results posted
• Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older PatientsActive, not recruitingNCT05823571Phase 1
• Studying Fentanyl in Patients With CancerTerminatedNCT00899951
• Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute LeukemiasTerminatedNCT00852709Phase 1
• Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative DisordersCompletedNCT00293410Phase 1
• Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic CancerCompletedNCT00265837Phase 3
• Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic CancerCompletedNCT00255710Phase 1
• 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT00077558Phase 1
• MS-275 in Treating Patients With Hematologic CancerCompletedNCT00015925Phase 1
• Phenylbutyrate and Tretinoin in Treating Patients With Hematologic CancerCompletedNCT00006239Phase 1
• Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic CancerCompletedNCT00006042Phase 1
• Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT00004871Phase 1
• Sargramostim After Bone Marrow Transplantation in Treating Patients With Myelodysplastic SyndromeCompletedNCT00003961Phase 2
• Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic CancerCompletedNCT00003243Phase 1